Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Key Inclusion Criteria: * Demonstrated a response (CR, CRu, or PR) on Study 114-NH-301 (Galiximab in combination with Rituximab compared with Rituximab in combination with Placebo) and then relapsed or progressed with a TTP \>=6 months. Relapsed disease is defined as documented disease progression using the International Workshop Response Criteria (IWRC). * Bidimensionally measurable disease with at least 1 lesion \>=2.0 cm in a single dimension. * Acceptable hematologic, hepatic, and renal function. Key Exclusion Criteria: * Any lymphoma therapy between Final Visit on Study 114-NH-301 and Study Day 1 of this retreatment study. * Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to Study Day 1. * Transfusion-dependent subjects. * Presence of central nervous system (CNS) lymphoma. * Histologic transformation. * Presence of pleural or peritoneal effusion with positive cytology for lymphoma. * Another primary malignancy requiring active treatment. * Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions that would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor. * New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to Study Day 1.